Closing the Infrastructure Gap in Investigator-Initiated Trials

Abstract

Investigator-initiated trials are uniquely unsuited to a patchwork of Google Drive folders, Excel worksheets, and consumer-grade software. Industry sponsors deploy full technology stacks—electronic data capture systems, regulatory document repositories, clinical trial management systems—while academic investigators retrofit consumer tools never designed for regulated research.

This commentary examines the structural technology gap facing independent clinical research and argues that purpose-built platforms are essential to sustaining investigator-initiated trials.

Introduction

Clinical trials have long been considered the province of pharmaceutical companies with unlimited budgets and bottomless R&D pipelines. NIH funding has contributed to published research associated with every new drug approved by the FDA in recent years, with collective grant funding exceeding $100 billion over the study period.¹

Industry sponsors finance megatrials designed to answer competitive drug development questions. Whether large or small, industry-sponsored trials enjoy robust infrastructure including clinical trial management systems, professional study coordinators, data managers, and enterprise technologies that exist outside the constraints of consumer platforms such as Excel.

By contrast, many investigator-initiated trials (IITs) shoulder equivalent regulatory requirements while being operated by a single study coordinator—and are lucky if they have access to consistent systems from one trial to the next. IITs don’t receive bespoke software upgrades blessed by the CEO.

Many platforms used by investigators were never designed with clinical trials in mind. The consequence is a widening infrastructure gap that leaves independent investigators operating complicated clinical studies with outdated technology and workflows designed for industrial-scale budgets, teams, and priorities.

It’s time we expected better for investigator-initiated trials.

The Regulatory Reality

The disconnect begins with regulation: FDA guidelines make no distinction between investigator-initiated and industry-sponsored trials.² Good Clinical Practice applies to academic research regardless of funding source.

Institutional review boards exist to protect human research subjects, not drug company profits. And while you may be excused for missing a deadline when submitting your safety report on paper, the FDA maintains strict requirements around electronic records and electronic signatures under 21 CFR Part 11.³ All investigational studies must comply.

Modern investigator-initiated trials are complex, regulated research activities subject to the same oversight as big-budget drug development. They deserve—and scientifically demand—accessible technology platforms designed specifically for their operational and regulatory needs.

Trial Sponsors vs. Investigator-Sponsors

Large trial sponsors have resources and personnel dedicated to clinical research across enterprise operations. Clinical trials departments include experts in clinical operations, data management, biostatistics, regulatory affairs, and more.

Their technology stack reflects these teams: rather than shoehorn Microsoft Access into EDC service, pharmaceutical budgets allow customized clinical trial platforms purpose-built around sponsor needs. When an academic institution becomes the sponsor of record for a trial, clinical research responsibilities fall onto people running hospitals.

Many talented clinical investigators juggle researcher and clinician roles. But expecting smart clinicians to manually aggregate data from spreadsheets into primary analysis datasets reflects guidance from nearly 20 years ago.⁴

While enormous gains in CTMS adoption have been made over the past decade, pharmaceutical sponsors spend more on clinical trials each year than many academic medical centers spend on institutional IT budgets.⁵ Between clinician-investigators shouldering the dual burden of running hospitals and scientific studies, and enterprise budget allocations that would make a Fortune 500 CFO blush, there is a massive asymmetry in available tools and technology.

Too often, clinical investigators respond to these pressures by retrofitting off-label technology to clinical trial workflows. But the drug trial infrastructure has evolved to support pharmaceutical sponsors, not independent investigators.

Investigator-Initiated Trials Deserve Better Technology

REDCap democratized data capture. Prior to its release in 2004, industry-sponsored trials used purpose-built EDC systems priced for enterprise budgets, putting them out of reach for small investigator-led studies.

In response, REDCap was made available at no cost. The platform launched at Vanderbilt University in August 2004 and quickly expanded through a consortium-based sharing model.

By the time the first academic paper describing REDCap was published in 2009, the consortium included 27 active partner institutions supporting 286 translational research projects.⁴ Within a decade, that number would grow to over 3,200 partner organizations across 128 countries.⁶

With open-source availability and no financial barrier to adoption, REDCap grew rapidly, fueled by exactly the user base it was built for: small investigator-led studies without enterprise budgets. The irony is that REDCap solved the wrong problem.

Entry costs for EDC are no longer prohibitive. Modern platforms remove barriers to data capture, whether through custom web applications or hosted solutions that can launch trials within hours. Free platforms are not required to enable electronic data capture in 2026.

Instead of pioneering workflows that would replace spreadsheets entirely, REDCap became the de facto standard for EDC in academic research, putting thousands of studies on a platform that was never intended to manage a clinical trial.

Without question, hundreds of millions of patient records have been successfully captured using REDCap. The tool democratized data capture and provided academic researchers a foothold in electronic research workflows.

But capturing data is just one piece of clinical research. Investigators still manage documents in Google Drive or SharePoint, track enrollment using Excel, communicate via email, and juggle dozens of disconnected systems that shouldn’t be regulating your sunscreen let alone hosting patient data.

I don’t blame REDCap for filling voids that ought to be occupied by purpose-built platforms for investigator-initiated trials. Without these systems, researchers need every tool they can get.

But using band-aids as permanent fixtures paints an unfortunate picture of the current clinical research technology landscape.

Clinical Trial Management Systems Are One Tool in the Toolbox

Clinical trial management systems streamline trial operations by tracking enrollment, visit schedules, document storage, and financial reporting in centralized databases.⁵ These platforms handle everything from managing protocol variations across sites to ensuring investigators are paid on time.

They can even automate consent checks and generate submission-ready safety reports. CTMS platforms provide proven solutions to clinical research challenges, but only if your organization can afford to adopt one.

Consider current global CTMS market trends: total valuation is expected to grow from $1.41 billion in 2024 to $3.87 billion by 2032.⁷ Commercial CTMS platforms will expand to meet pharmaceutical sponsor demand.

No plans to adjust your medical center’s healthcare IT budget? You’ll be stuck in Excel.

The clinical trial management system industry is optimized for traditional trial sponsors. Academic sites are using CTMS, but adoption remains uneven. In one survey of clinical trial professionals, six in ten CRO respondents reported using a CTMS compared to only four in ten investigators, with cost cited as the primary barrier to adoption.⁸

As clinicians and scientists, we’re hacking clinical trial workflows using academic journals and duct tape. We accept sloppier technology just to reduce overhead.

We don’t have to sacrifice compliance or reporting quality to participate in clinical research. Innovators across the research technology industry recognize underserved markets, including independent investigators and decentralized clinical trials.⁷

With lower barriers to adoption and flexible pricing models, CTMS solutions can fit within academic budgets. That doesn’t mean we shouldn’t ask for more.

The Opportunity Ahead

We have only scratched the surface. Solutions have been proposed to address this problem, including establishing clinical trials units to centralize expertise and resources, or developing consortia across multiple institutions.⁹

Investing in infrastructure solves many of these problems at a program level, but individual investigators will always bear responsibility for their own trials. To improve clinical research, we must demand better technology.

We deserve platforms that match the science conducted within our walls. Platform features must be tailored for the realities of academic research: limited budgets, dual clinical and research duties, and small teams.

Commercial technology markets serve large sponsors and CROs. Clinical trial ecosystems will continue to evolve toward these users unless we, as a research community, make our needs known.

Technology exists. The question is whether we’ll demand access to it.

References

1. Galkina Cleary E, Beierlein JM, Khanuja NS, McNamee LM, Ledley FD. Contribution of NIH funding to new drug approvals 2010–2016. Proc Natl Acad Sci U S A. 2018;115(10):2329-2334. doi:10.1073/pnas.1715368115

2. US Food and Drug Administration. E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1). Guidance for Industry. Published March 2018. Accessed March 15, 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r2-good-clinical-practice-integrated-addendum-ich-e6r1

3. US Food and Drug Administration. Electronic systems, electronic records, and electronic signatures in clinical investigations: questions and answers. Guidance for Industry. Revision 1. Published October 2024. Accessed March 15, 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-systems-electronic-records-and-electronic-signatures-clinical-investigations-questions

4. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research Electronic Data Capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-381. doi:10.1016/j.jbi.2008.08.010

5. Cascade E, Wurdeman J. Looking at clinical trial technology through a site lens. Clinical Researcher. 2024;38(1). Published February 16, 2024. Accessed March 15, 2026. https://acrpnet.org/2024/02/16/looking-at-clinical-trial-technology-through-a-site-lens

6. Harris PA, Taylor R, Minor BL, et al; REDCap Consortium. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi:10.1016/j.jbi.2019.103208

7. Data Bridge Market Research. Clinical trial management system (CTMS) market – global market size, share, and trends analysis report – industry overview and forecast to 2032. Published 2024. Accessed March 15, 2026. https://www.databridgemarketresearch.com/reports/global-clinical-trial-management-system-market

8. Park JS, Moon SJ, Lee JH, et al. The first step to the powers for clinical trials: a survey on the current and future Clinical Trial Management System. Transl Clin Pharmacol. 2018;26(2):86-92. doi:10.12793/tcp.2018.26.2.86

9. Konwar M, Bose D, Gogtay NJ, Thatte UM. Investigator-initiated studies: challenges and solutions. Perspect Clin Res. 2018;9(4):179-183. doi:10.4103/picr.PICR_106_18